The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy ... partly due to the seasonality of FluMist and increased before it is supplied to Sanofi, following a very ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...